Medical company LivaNova are pumped about their latest results for treatment-resistant bipolar disorder sufferers.
They recently announced the publication of a new study that showed adding vagus nerve stimulation (VNS) therapy to treatment-as-usual significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD).
Patients who received adjunctive VNS therapy responded more quickly and experienced more durable antidepressant effects than those just receiving treatment-as-usual (TAU). The study concluded that adjunctive VNS therapy is an efficacious antidepressant treatment for patients with TRBD.
“LivaNova is dedicated to helping patients who suffer from treatment-resistant bipolar depression. We are heartened to see that the results of this five-year study show that patients receiving adjunctive VNS therapy were more likely to respond and experienced a faster and more durable response than patients treated with TAU alone. Moreover, the study reconfirmed that adjunctive VNS therapy significantly lowers suicidality, a very important and key factor when considering the overall positive impact on the lives of patients and their loved ones.”Bryan Olin, SVP for clinical, quality and regulatory affairs, LivaNova